This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freda, P. U. Articles by Wardlaw, S. L. Search for Related Content PubMed PubMed Citation Articles by Freda, P. U. Articles by Wardlaw, S. L.

Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly¹

Department of Medicine, Columbia College of Physicians and Surgeons, New York, New York 10032, and the Department of Neurosurgery, Mount Sinai Medical Center, New York, New York 10029

Address all correspondence and requests for reprints to: Dr. Pamela U. Freda, Department of Medicine, Columbia College of Physicians and Surgeons, 630 West 168th Street, New York, New York 10032.

Traditionally, suppression of GH measured by polyclonal RIA to less than 2.0 µg/L after oral glucose was accepted as evidence of remission after transsphenoidal surgery for acromegaly. Recently, with newer, more sensitive GH assays, a cut-off of less than 1.0 µg/L has been suggested. With the development of accurate insulin-like growth factor I (IGF-I) and IGF-binding protein-3 (IGFBP-3) assays, additional tools are now available for assessing postoperative GH secretion. There has, however, never been a systematic comparison of sensitive GH, IGF-I, and IGFBP-3 assays in defining disease status in a large cohort of postoperative patients with acromegaly. Therefore, we evaluated how the use of modern assays impacts on our assessment of disease activity in these patients.

Sixty postoperative subjects with acromegaly and 25 age-matched healthy subjects were evaluated with nadir GH levels after 100 g oral glucose as well as baseline IGF-I and IGFBP-3 levels. GH was assayed by polyclonal RIA, sensitive immunoradiometric assay (IRMA), and highly sensitive enzyme-linked immunosorbent assay. The mean nadir GH determined by IRMA was 0.09 ± 0.004 µg/L in the healthy subjects, with the upper limit of the normal nadir being 0.14 µg/L (mean + 2 SD). Subjects with acromegaly were divided into those with active disease (n = 22), defined by elevated IGF-I levels, and those in remission (n = 38), defined by normal IGF-I levels. GH determined by IRMA failed to suppress into the normal range defined by our healthy subjects in all patients with active disease; nadir GH determined by IRMA ranged from 0.33–5.0 µg/L in this group. In 50% of the active group, nadir GH levels determined by IRMA were less than 1.0 µg/L, a GH nadir previously considered normal by strict criteria. When nadir GH levels in the subjects with active disease were measured by polyclonal RIA, there was overlap with the range of RIA values in the healthy subjects. Thus, the IRMA was superior to the RIA in that the overlap between these two groups was eliminated. Subjects with acromegaly in remission included those with normal GH suppression (n = 23; mean nadir GH by IRMA, 0.10 ± 0.006 µg/L) and others with abnormal GH suppression by IRMA (n = 15; mean nadir GH by IRMA, 0.35 ± 0.07 µg/L). The latter group may have persistent GH dysregulation detected by the sensitive IRMA. GH levels measured by enzyme-linked immunosorbent assay confirmed the IRMA results. IGFBP-3 levels were significantly higher in subjects with active acromegaly (4940 ± 301 µg/L) vs. those in healthy subjects (2887 ± 153 µg/L; P < 0.0001) and those in the subjects in remission (2966 µg/L; P < 0.0001). IGFBP-3 levels correlated overall with IGF-I levels (r = 0.765; P < 0.0001), but IGFBP-3 levels were not predictive of disease status because 32% of the subjects with active acromegaly had normal IGFBP-3 levels. In addition, failure of GH to suppress adequately was not associated with a higher IGFBP-3 level among the subjects in remission.

These data indicate that the IRMA is superior to the RIA in distinguishing between patients with active disease (defined by elevated IGF-I levels) and healthy subjects. We also show that GH levels after oral glucose measured with highly sensitive GH assays can be much lower in subjects with active disease than previously believed; values less than 1.0 µg/L may be found in up to 50% of patients. In addition, in 39% of patients in apparent remission with normal IGF-I levels, GH determined by highly sensitive assays fails to suppress normally; it remains to be determined whether these patients are at higher risk for recurrence of active disease.

This article has been cited by other articles:

				J. D. Carmichael, V. S. Bonert, J. M. Mirocha, and S. Melmed The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 523 - 527. [Abstract] [Full Text] [PDF]

				A. M. Arafat, M. Mohlig, M. O. Weickert, F. H. Perschel, J. Purschwitz, J. Spranger, C. J. Strasburger, C. Schofl, and A. F. H. Pfeiffer Growth Hormone Response during Oral Glucose Tolerance Test: The Impact of Assay Method on the Estimation of Reference Values in Patients with Acromegaly and in Healthy Controls, and the Role of Gender, Age, and Body Mass Index J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1254 - 1262. [Abstract] [Full Text] [PDF]

				O. Alexopoulou, M. Bex, R. Abs, G. T'Sjoen, B. Velkeniers, and D. Maiter Divergence between Growth Hormone and Insulin-Like Growth Factor-I Concentrations in the Follow-Up of Acromegaly J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1324 - 1330. [Abstract] [Full Text] [PDF]

				M. Misra, J. Cord, R. Prabhakaran, K. K. Miller, and A. Klibanski Growth Hormone Suppression after an Oral Glucose Load in Children J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4623 - 4629. [Abstract] [Full Text] [PDF]

				R. Kauppinen-Makelin, T. Sane, H. Sintonen, H. Markkanen, M. J. Valimaki, E. Loyttyniemi, L. Niskanen, A. Reunanen, U.-H. Stenman, and and the Finnish Acromegaly Study Group Quality of Life in Treated Patients with Acromegaly J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3891 - 3896. [Abstract] [Full Text] [PDF]

				L. J. Woodhouse, A. Mukherjee, S. M. Shalet, and S. Ezzat The Influence of Growth Hormone Status on Physical Impairments, Functional Limitations, and Health-Related Quality of Life in Adults Endocr. Rev., May 1, 2006; 27(3): 287 - 317. [Abstract] [Full Text] [PDF]

				H. Markkanen, T. Pekkarinen, M. J. Valimaki, H. Alfthan, R. Kauppinen-Makelin, T. Sane, and U.-H. Stenman Effect of Sex and Assay Method on Serum Concentrations of Growth Hormone in Patients with Acromegaly and in Healthy Controls Clin. Chem., March 1, 2006; 52(3): 468 - 473. [Abstract] [Full Text] [PDF]

				R. A. Feelders, M. Bidlingmaier, C. J. Strasburger, J. A. M. J. L. Janssen, P. Uitterlinden, L. J. Hofland, S. W. J. Lamberts, A. J. van der Lely, and W. W. de Herder Postoperative Evaluation of Patients with Acromegaly: Clinical Significance and Timing of Oral Glucose Tolerance Testing and Measurement of (Free) Insulin-Like Growth Factor I, Acid-Labile Subunit, and Growth Hormone-Binding Protein Levels J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6480 - 6489. [Abstract] [Full Text] [PDF]

				J. J. Puder, S. Nilavar, K. D. Post, and P. U. Freda Relationship between Disease-Related Morbidity and Biochemical Markers of Activity in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 1972 - 1978. [Abstract] [Full Text] [PDF]

				S. Wang, F. Paris, C. S. Sultan, R. X.-D. Song, L. M. Demers, B. Sundaram, J. Settlage, S. Ohorodnik, and R. J. Santen Recombinant Cell Ultrasensitive Bioassay for Measurement of Estrogens in Postmenopausal Women J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1407 - 1413. [Abstract] [Full Text] [PDF]

				C. L. Ronchi, V. Varca, C. Giavoli, P. Epaminonda, P. Beck-Peccoz, A. Spada, and M. Arosio Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1377 - 1382. [Abstract] [Full Text] [PDF]

				S. Jehle, C. M. Reyes, R. E. Sundeen, and P. U. Freda Alternate-Day Administration of Pegvisomant Maintains Normal Serum Insulin-Like Growth Factor-I Levels in Patients with Acromegaly J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1588 - 1593. [Abstract] [Full Text] [PDF]

				D. R. Clemmons and C. Strasburger Monitoring the Response to Treatment in Acromegaly J. Clin. Endocrinol. Metab., November 1, 2004; 89(11): 5289 - 5291. [Full Text] [PDF]

				I. Kreitschmann-Andermahr, C. Hoff, B. Saller, S. Niggemeier, S. Pruemper, B. O. Hutter, V. Rohde, A. Gressner, S. Matern, and J. M. Gilsbach Prevalence of Pituitary Deficiency in Patients after Aneurysmal Subarachnoid Hemorrhage J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4986 - 4992. [Abstract] [Full Text] [PDF]

				E. J. M. Zirkzee, E. P. M. Corssmit, N. R. Biermasz, P. A. Brouwer, F. T. Wiggers-De Bruine, L. J. M. Kroft, M. A. Van Buchem, F. Roelfsema, A. M. Pereira, J. W. A. Smit, et al. Pituitary Magnetic Resonance Imaging Is Not Required in the Postoperative Follow-Up of Acromegalic Patients with Long-Term Biochemical Cure after Transsphenoidal Surgery J. Clin. Endocrinol. Metab., September 1, 2004; 89(9): 4320 - 4324. [Abstract] [Full Text] [PDF]

				M. Misra, K. K. Miller, D. B. Herzog, K. Ramaswamy, A. Aggarwal, C. Almazan, G. Neubauer, J. Breu, and A. Klibanski Growth Hormone and Ghrelin Responses to an Oral Glucose Load in Adolescent Girls with Anorexia Nervosa and Controls J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1605 - 1612. [Abstract] [Full Text] [PDF]

				J. Ayuk, R. N. Clayton, G. Holder, M. C. Sheppard, P. M. Stewart, and A. S. Bates Growth Hormone and Pituitary Radiotherapy, But Not Serum Insulin-Like Growth Factor-I Concentrations, Predict Excess Mortality in Patients with Acromegaly J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1613 - 1617. [Abstract] [Full Text] [PDF]

				P. U. Freda, A. T. Nuruzzaman, C. M. Reyes, R. E. Sundeen, and K. D. Post Significance of "Abnormal" Nadir Growth Hormone Levels after Oral Glucose in Postoperative Patients with Acromegaly in Remission with Normal Insulin-Like Growth Factor-I Levels J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 495 - 500. [Abstract] [Full Text] [PDF]

				O. Serri, C. Beauregard, and J. Hardy Long-Term Biochemical Status and Disease-Related Morbidity in 53 Postoperative Patients with Acromegaly J. Clin. Endocrinol. Metab., February 1, 2004; 89(2): 658 - 661. [Abstract] [Full Text] [PDF]

				N. R. Biermasz, A. M. Pereira, M. Frolich, J. A. Romijn, J. D. Veldhuis, and F. Roelfsema Octreotide represses secretory-burst mass and nonpulsatile secretion but does not restore event frequency or orderly GH secretion in acromegaly Am J Physiol Endocrinol Metab, January 1, 2004; 286(1): E25 - E30. [Abstract] [Full Text]

				D. R. Clemmons, K. Chihara, P. U. Freda, K. K. Y. Ho, A. Klibanski, S. Melmed, S. M. Shalet, C. J. Strasburger, P. J. Trainer, and M. O. Thorner Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4759 - 4767. [Abstract] [Full Text] [PDF]

				P. De, D. A. Rees, N. Davies, R. John, J. Neal, R. G. Mills, J. Vafidis, J. S. Davies, and M. F. Scanlon Transsphenoidal Surgery for Acromegaly in Wales: Results Based on Stringent Criteria of Remission J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3567 - 3572. [Abstract] [Full Text] [PDF]

				P. U. Freda, C. M. Reyes, I. M. Conwell, R. E. Sundeen, and S. L. Wardlaw Serum Ghrelin Levels in Acromegaly: Effects of Surgical and Long-Acting Octreotide Therapy J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 2037 - 2044. [Abstract] [Full Text] [PDF]

				P. J. Trainer Acromegaly--Consensus, What Consensus? J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3534 - 3536. [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. DeMott-Friberg, W. F. Chandler, and A. L. Barkan Acromegaly with Apparently Normal GH Secretion: Implications for Diagnosis and Follow-Up J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3537 - 3542. [Abstract] [Full Text] [PDF]

				P. U. Freda Somatostatin Analogs in Acromegaly J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3013 - 3018. [Full Text] [PDF]

				A. C. F. Costa, A. Rossi, C. E. Martinelli Jr., H. R. Machado, and A. C. Moreira Assessment of Disease Activity in Treated Acromegalic Patients Using a Sensitive GH Assay: Should We Achieve Strict Normal GH Levels for a Biochemical Cure? J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3142 - 3147. [Abstract] [Full Text] [PDF]

				J. Kreutzer, M. L. Vance, M. B. S. Lopes, and E. R. Laws Jr. Surgical Management of GH-Secreting Pituitary Adenomas: An Outcome Study Using Modern Remission Criteria J. Clin. Endocrinol. Metab., September 1, 2001; 86(9): 4072 - 4077. [Abstract] [Full Text] [PDF]

				P. Marzullo, C. Di Somma, K. L. Pratt, J. Khosravi, A. Diamandis, G. Lombardi, A. Colao, and R. G. Rosenfeld Usefulness of Different Biochemical Markers of the Insulin-Like Growth Factor (IGF) Family in Diagnosing Growth Hormone Excess and Deficiency in Adults J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3001 - 3008. [Abstract] [Full Text] [PDF]

				G. A. Kaltsas, A. M. Isidori, D. Florakis, P. J. Trainer, C. Camacho-Hubner, F. Afshar, I. Sabin, J. P. Jenkins, S. L. Chew, J. P. Monson, et al. Predictors of the Outcome of Surgical Treatment in Acromegaly and the Value of the Mean Growth Hormone Day Curve in Assessing Postoperative Disease Activity J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1645 - 1652. [Abstract] [Full Text]

				N. R. Biermasz, H. van Dulken, and F. Roelfsema Ten-Year Follow-Up Results of Transsphenoidal Microsurgery in Acromegaly J. Clin. Endocrinol. Metab., December 1, 2000; 85(12): 4596 - 4602. [Abstract] [Full Text]

				G. Barrande, M. Pittino-Lungo, J. Coste, D. Ponvert, X. Bertagna, J. P. Luton, and J. Bertherat Hormonal and Metabolic Effects of Radiotherapy in Acromegaly: Long-Term Results in 128 Patients Followed in a Single Center J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3779 - 3785. [Abstract] [Full Text]

				N. R. Biermasz, H. van Dulken, and F. Roelfsema Long-Term Follow-Up Results of Postoperative Radiotherapy in 36 Patients with Acromegaly J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2476 - 2482. [Abstract] [Full Text]

				J. S. Powell, S. L. Wardlaw, K. D. Post, and P. U. Freda Outcome of Radiotherapy for Acromegaly Using Normalization of Insulin-Like Growth Factor I to Define Cure J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 2068 - 2071. [Abstract] [Full Text]

				A. Giustina, A. Barkan, F. F. Casanueva, F. Cavagnini, L. Frohman, K. Ho, J. Veldhuis, J. Wass, K. von Werder, and S. Melmed Criteria for Cure of Acromegaly: A Consensus Statement{dagger} J. Clin. Endocrinol. Metab., February 1, 2000; 85(2): 526 - 529. [Abstract] [Full Text]

				P. U. Freda and S. L. Wardlaw Diagnosis and Treatment of Pituitary Tumors J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3859 - 3866. [Full Text]